Myocet Liposomal (Doxorubicin Hydrochloride)

Doxorubicin hydrochloride intercalates into DNA and blocks topoisomerase II, halting DNA replication and transcription. The drug also generates free radicals that damage cellular components, leading to tumour cell death.

The specific dose of Myocet Liposomal is determined by the prescribing oncologist based on the patient’s clinical condition, body surface area, and treatment protocol. Dosage regimens are individualized and should follow local prescribing guidelines.

Myocet Liposomal is generally contraindicated in pregnancy and lactation because of potential fetal and infant toxicity. It should only be used if the potential benefit justifies the risk, and women of child‑bearing potential should use effective contraception.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Myocet Liposomal encapsulates doxorubicin in liposomes, which can reduce peak plasma concentrations and limit exposure to healthy tissues. This formulation often results in a lower incidence of certain toxicities, such as cardiotoxicity, while maintaining comparable antitumour efficacy to conventional doxorubicin.

Myocet Liposomal should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Prior to administration, the product should be inspected for particulate matter and used within the time frame recommended by the manufacturer.

Myocet Liposomal is given as an intravenous infusion, typically diluted in an appropriate compatible solution and administered over a prescribed period. Administration should be performed by qualified healthcare professionals in a setting equipped for infusion therapy and monitoring.

The most serious risks include cardiotoxicity, which can lead to irreversible heart failure, severe neutropenia increasing infection risk, and rare events such as secondary leukemia. Patients should be closely monitored for cardiac function and blood counts throughout treatment.

Myocet Liposomal is contraindicated in patients with known hypersensitivity to doxorubicin or any component of the formulation, in those with pre‑existing severe cardiac disease, and in pregnant or breastfeeding women unless the benefits outweigh the risks.